Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | HTR7 | P34969 | 5/20 | 0.45 |
| ▸ | HRH2 | P25021 | 5/20 | 0.45 |
| ▸ | HRH1 | P35367 | 5/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126384 | 0.97 | KCNH2 (0.63) | KCNH2HTR7HRH2HRH1ALDH1A1 | |
| SCHEMBL3131043 | 0.94 | KCNH2 (0.61) | KCNH2HTR7HRH2HRH1HTR1A | |
| SCHEMBL3120395 | 0.93 | KCNH2 (0.68) | KCNH2HRH2HRH1ALDH1A1MEN1 | |
| SCHEMBL3125321 | 0.90 | KCNH2 (0.68) | KCNH2HTR7HRH2HRH1HTR1A | |
| SCHEMBL3131778 | 0.89 | KCNH2 (0.65) | KCNH2HRH2HRH1MEN1KCNA5 | |
| SCHEMBL3128803 | 0.88 | KCNH2 (0.55) | KCNH2HRH2HRH1ALDH1A1MEN1 | |
| SCHEMBL3126031 | 0.88 | KCNH2 (0.72) | KCNH2HRH2HRH1HRH3 | |
| SCHEMBL3131066 | 0.87 | KCNH2 (0.71) | KCNH2HTR7HRH2HRH1HTR1A | |
| SCHEMBL3127820 | 0.87 | KCNH2 (0.71) | KCNH2HTR7HRH2HRH1ALDH1A1 | |
| SCHEMBL3123057 | 0.86 | KCNH2 (0.54) | KCNH2HTR7HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765832-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123748-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | claimed |
| US-7648985-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1765832-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123748-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HTR7 4429/4885HRH2 616/4885 |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HTR7 4429/4885HRH2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.